Sandoz’s Jubbonti and Wyost Approved as First Interchangeable Biosimilars to Amgen’s Bone Drugs Prolia and Xgeva
XTalks
MARCH 8, 2024
The US Food and Drug Administration (FDA) has granted approval to two of Sandoz’s biosimilars to Amgen’s blockbuster bone drugs Prolia (denosumab) and Xgeva (denosumab). Risk factors include aging, hormonal changes, low body weight, low calcium intake and use of certain medications.
Let's personalize your content